Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | ALDH1A3 | P47895 | 3/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL116316 | 0.78 | ALDH1A1 (0.46) | ALDH1A1ALDH1A3S1PR4ALDH3A1HSD17B10 | |
| SCHEMBL29436325 | 0.78 | ALDH1A1 (0.46) | ALDH1A1ALDH1A3S1PR4ALDH3A1HSD17B10 | |
| SCHEMBL14944013 | 0.76 | ALDH1A1 (0.41) | ALDH1A1ALDH1A3ALDH3A1HSD17B10L3MBTL1 | |
| SCHEMBL29581019 | 0.75 | ALDH1A1 (0.43) | ALDH1A1ALDH1A3ALDH3A1HSD17B10L3MBTL1 | |
| SCHEMBL336038 | 0.75 | ALDH1A1 (0.43) | ALDH1A1ALDH1A3ALDH3A1HSD17B10L3MBTL1 | |
| SCHEMBL4325787 | 0.75 | ALDH1A1 (0.43) | ALDH1A1ALDH1A3ALDH3A1HSD17B10L3MBTL1 | |
| SCHEMBL29953607 | 0.75 | ALDH1A1 (0.43) | ALDH1A1ALDH1A3ALDH3A1HSD17B10L3MBTL1 | |
| SCHEMBL29954683 | 0.75 | ALDH1A1 (0.43) | ALDH1A1ALDH1A3ALDH3A1HSD17B10L3MBTL1 | |
| SCHEMBL7992585 | 0.75 | ALDH1A1 (0.43) | ALDH1A1ALDH1A3ALDH3A1HSD17B10L3MBTL1 | |
| SCHEMBL9446729 | 0.75 | ALDH1A1 (0.43) | ALDH1A1ALDH1A3ALDH3A1HSD17B10L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300476-B1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LTD (GB) | 2014-01-08 | — | — | EP | disclosed |
| EP-2300476-B1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LTD (GB) | 2014-01-08 | — | — | EP | disclosed |
| CN-102105473-B | Tricyclic nitrogen containing compounds and their use as antibacterials | GLAXO GROUP LTD | 2013-05-08 | — | — | CN | disclosed |
| US-8097628-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-01-17 | — | — | US | disclosed |
| US-8097628-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-01-17 | — | — | US | disclosed |
| US-8097628-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-01-17 | — | — | US | disclosed |
| CN-102105473-A | Tricyclic nitrogen containing compounds and their use as antibacterials | GLAXO GROUP LTD | 2011-06-22 | — | — | CN | disclosed |
| EP-2300476-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS | Glaxo Group Limited (GB) | 2011-03-30 | — | — | EP | disclosed |
| US-20090306089-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-12-10 | — | — | US | disclosed |
| US-20090306089-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-12-10 | — | — | US | disclosed |
| US-20090306089-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-12-10 | — | — | US | disclosed |
| WO-2009141398-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009141398-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306089-A1 | COMPOUNDS | SDHA, NQO1, SDHB | ALDH1A1 612/4885ALDH1A3 1456/4885S1PR4 3597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.